Table 2.
Overall response to azacitidine.
| Variable | |
|---|---|
| ORR, % | |
| Total population (n = 15) | 47 |
| Patients with high-risk cytogenetics (n = 5) | 40 |
| Patients with intermediate-risk cytogenetics (n = 9) | 44 |
| Best response achieved in overall patient population, n (%)* | |
| CR | 3 (20) |
| PR | 2 (13) |
| HI | 2 (13) |
| NR | 8 (53) |
| Responses in high-risk cytogenetics group, n (%) | |
| CR | 1 (20) |
| PR | 0 (0) |
| HI | 1 (20) |
| NR | 3 (60) |
| Responses in intermediate-risk cytogenetics group, n (%) | |
| CR | 1 (11) |
| PR | 2 (22) |
| HI | 1 (11) |
| NR | 5 (56) |
| Median treatment duration, days (range) | 198 (13–724) |
| Median time to best response, days (range) | 95 (44–279) |
| Median OS, days (range) | |
| Total population | 355 (13–908) |
| Patients with high-risk cytogenetics | 167 (13–494) |
| Patients with intermediate-risk cytogenetics | 401 (13–908) |
| Responders to azacitidine | 532 (120–908) |
| Patients maintaining ECOG PS of 0–2 during treatment, n (%) | 12 (80) |
| Patients achieving independence from PRBC transfusion while receiving azacitidine, n (%) | 4 (26) |
| Patients achieving independence from platelet transfusion while receiving azacitidine, n (%) | 6 (40) |
CR, complete remission; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HI, hematologic improvement; ORR, overall response rate; OS, overall survival; PR, partial remission; PRBC, packed red blood cells.
*
Percentages do not total 100 because of rounding.